Enjoy complimentary customisation on priority with our Enterprise License!
The global plasma fractionation market size is estimated to grow by USD 10.00 billion at a CAGR of 6.09% between 2023 and 2028. The plasma industry witnesses growth with a specialized plasma therapy manufacturing facility producing immunoglobulins and albumins for therapeutic areas like respiratory diseases and liver diseases. AATD (Alpha-1-antitrypsin deficiency) and chronic obstructive pulmonary disease (COPD) are targeted, along with rare diseases and chronic disorders. Blood plasma, collected at plasma collection centers, undergoes plasma fractionation to yield essential components like anticoagulant factors and prothrombin complex.
Primary immunodeficiency conditions benefit from subcutaneous immunoglobulin (SCIG) treatments. This comprehensive approach supports patients suffering from emphysema and other lung diseases, underscoring the vital role of plasma therapy in managing diverse medical conditions.
To learn more about this report, Download Report Sample
The market share growth by the immunoglobulins segment will be significant during the forecast period. Immunoglobulins, also known as antibodies, play an important role in the immune system to the body's defense against infections and diseases in the global market. Immunoglobulins, particularly intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), have been essential therapeutic products derived from plasma-fractionation.
Get a glance at the market contribution of various segments Download PDF Sample
The immunoglobulins segment was valued at USD 11.52 billion in 2018. Furthermore, the rising prevalence of immunodeficiency and autoimmune disorders globally has contributed to an increased demand for immunoglobulin products. This growing patient pool has driven the production and market growth of immunoglobulins. Thus, the growing awareness of the therapeutic benefits of plasma-derived products, including immunoglobulins, has led to an increased demand for these therapies, which will boost the segment to further propel the global market during the forecast period.
Plasma-derived immunoglobulins are employed in the treatment of various autoimmune diseases like Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and type 1 diabetes. The immunomodulatory effects of immunoglobulins help to regulate the immune system and mitigate the effects of autoimmune responses. In addition, the field of immunotherapy, which involves harnessing the immune system to treat diseases such as cancer, is a rapidly evolving area. Plasma-derived immunoglobulins, along with other immunotherapeutic approaches, contribute to research and development efforts, which will drive the growth of the immunology segment in the global market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In North America, countries such as the US, Canada, and Mexico are the major markets for the market as the countries have established plasma collection centers and a culture of voluntary plasma donation, ensuring a sufficient and consistent supply of plasma for fractionation. In addition, growth in the end-uses, including by governments and non-governmental organizations (NGOs), also drives the growth of the regional market.
Additionally, with an increase in the number of hospitals and the convenience provided by them, hospitals are expanding their services related to medical care. Medical care includes surgical procedures that involve blood transfusions, thus spurring the demand for plasma-fractionation in hospitals. Hence, such factors are expected to drive market growth in this region during the forecast period.
Market growth is driven by the increasing demand for plasma-derived products like immunoglobulins and albumins, essential in therapeutic areas including respiratory diseases, AATD (Alpha-1-antitrypsin deficiency), and liver diseases. Conditions such as lung diseases, emphysema, and COPD necessitate effective treatments sourced from blood plasma. Anticoagulant factors like prothrombin complex and thrombin aid in managing rare diseases and chronic disorders.
Primary immunodeficiency disorders benefit from Subcutaneous Immunoglobulin (SCIG) therapy, obtainable from plasma collection centers. The Plasma industry, facilitated by plasma therapy manufacturing facilities, thrives on plasma fractionation, ensuring the availability of vital components for medical treatments and interventions.
The market witnesses growth driven by the rising prevalence of lung diseases and hepatic conditions, including Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD). Plasma-derived therapies, such as immuno globulins and albumins, address these ailments. Plasma collection centers and inventories play a pivotal role in sourcing raw materials.
Anticoagulant factors like prothrombin complex and thrombin are crucial for hemostasis in conditions like Von Willebrand Disease and hemophilia. Market research and growth analysis, guided by organizations like the World Health Organization (WHO), steer advancements in plasma fractionation, catering to diverse medical needs and fostering market expansion.
The growing elderly population and related disorders is the primary trend shaping market growth. The elderly population is more susceptible to age-related chronic diseases, including immune disorders, neurological conditions, and autoimmune diseases. Plasma-derived products, such as immunoglobulins and clotting factors, are often used in the management of these conditions. The elderly are expected to experience a higher incidence of primary immunodeficiency disorders (PIDs), where the immune system is compromised. Immunoglobulin replacement therapy derived from plasma fractionation is a common treatment for PIDs.
Furthermore, plasma-derived products are used in the management of chronic diseases that are more prevalent in older age groups. These products support patients in maintaining a better quality of life and managing the complications associated with chronic illnesses. Hence, the growing elderly population and related disorders will play a significant role in fueling the growth of the global market during the forecast period.
Stringent government regulations regarding the safety of plasma-derived products are a challenge that affects market growth. Stringent government regulations are crucial for ensuring the safety and quality of plasma-derived products, they can pose challenges and complexities for market players. Meeting and maintaining compliance with evolving regulatory standards can be resource-intensive for vendors. This is expected to involve significant investments in infrastructure, quality control measures, and continuous monitoring.
Furthermore, achieving harmonization across different regions involves navigating diverse regulatory landscapes. Preparing for and undergoing regulatory inspections can be demanding. Non-compliance is expected to lead to regulatory actions, affecting market access and reputation. Thus, such factors are expected to impede the growth of the global market during the forecast period.
The market analysis and report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
ADMA Biologics Inc.: The company offers plasma fractionation specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market plays a vital role in various therapeutic areas, including respiratory diseases, liver diseases, and hemato-oncology. With a focus on treating conditions like AATD (Alpha-1-antitrypsin deficiency), emphysema, and hematological disorders, plasma-derived therapies are in high demand.
Plasma collection centers ensure a steady supply of blood plasma for fractionation, supported by regulatory authorities adhering to WHO guidelines to maintain quality and safety. Raw material suppliers play a crucial role in sourcing materials for plasma donation centers and biopharmaceutical manufacturers.
Innovations in plasma fractionation technologies, such as ethanol fractionation and automation, enhance efficiency and scalability for plasma fractionators and plasma facilities. The market landscape encompasses large companies like Baxter, mid-sized companies, and small companies, along with contract service providers catering to clinical research laboratories and academic institutes.
From diagnostic techniques like CT scanning to therapeutic interventions using recombinant factors like Kovaltry, the market continues to evolve, addressing a wide range of chronic disorders and rare diseases with precision and efficacy.
The market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
Market Scope |
|
Report Coverage |
Details |
Page number |
163 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.09% |
market forecast 2024-2028 |
USD 10 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.81 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 34% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., CSL Ltd., Emergent BioSolutions Inc., GC Biopharma corp. , Grifols SA, Hemarus Plasma, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A, LFB SA, Merck KGaA, Mitsubishi Chemical Group Corp., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions Netherlands BV, Sanquin, SK Inc., Takeda Pharmaceutical Co. Ltd., and Virchow Laboratories Ltd. |
Market dynamics |
Parent market trends and analysis, market growth and forecasting inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.